Today's Updates
Q&A: Mucus Plugging, Multimorbidity, and GOLD 2027, With Gerard Criner, MD
RENEW: Blinded Interim Data Show FVC Trends With LTI-03 in IPF
Anaphylaxis Reporting Varies Across Respiratory Biologics In FAERS
Angela Lek, PhD, chief research officer at the Muscular Dystrophy Association, discussed how the 2027 MDA Clinical and Scientific Conference agenda reflects key themes in neuromuscular medicine.
In the prespecified mild subgroup of HOPE, 40-Hz gamma sensory stimulation was associated with 56% slowing on the ADCS-ADL and 47% slowing on the CDR-SB vs sham at 12 months.
Peer-reviewed results from the phase 3 X-TOLE2 trial, published in JAMA Neurology, detail azetukalner's seizure reduction and dose-dependent adverse events in adults with focal epilepsy.
The FDA approved Beren Therapeutics' adrabetadex, marketed as Lembaz, to reduce the risk of death in patients with infantile-onset Niemann-Pick disease type C.
Phase 3 POLARIS-AD results show AR1001 benefit on CDR-SB in a prespecified monotherapy population, but not in the overall early Alzheimer disease population.
The senior director of research at the Muscular Dystrophy Association discussed what the newly approved once-weekly C5 inhibitor adds to generalized myasthenia gravis care.
At an HCPLive and NeurologyLive Clinical Forum in Orlando, David Z. Rose, MD, of USF Morsani College of Medicine, discussed residual recurrence risk, dual antiplatelet therapy duration, and factor XIa inhibition in noncardioembolic stroke.
Oncology
A scientific review of fluorescence-lifetime imaging as an adjunct for distinguishing residual tumor from treatment-altered fibrosis during cancer surgery.
A clinical review of rehabilitation, psychosocial care, and evidence-informed strategies that support social reintegration and self-confidence after head and neck cancer treatment.
A clinical review of immune editing, tumor evolution, immune escape, biomarkers, treatment resistance, and emerging immunotherapy strategies.
A professional review of targeted protein degraders, including PROTACs, in hormone-driven breast and prostate cancers, with mechanisms, evidence, risks, and clinical implications.
Dr. Harish P and 1 more
Dr. Vijay Agarwal and 1 more
Dr Suvir Singh
Dr Vijay Agarwal and 1 more
Dr. Todd Bauer and 1 more
Dr. Poonam Patil and 1 more
Fastest Growing Medical Platform for Doctors
Address : Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone : +1-415-463-3094
Email : anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
To get started please enter your email ID
By entering your details you agree to our
Please check your email for the four-digit security code and enter it below.
Didn't receive a code? Resend OTP
Join to enhance your clinical skills and gain specialized in-depth medical knowledge
Country
State
64824 This Month
2524 Today